Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient
The COVID-19 pandemic has had an unprecedented health and economic impact and there are currently no approved therapies. We have isolated an antibody, EY6A, from an individual convalescing from COVID-19 and have shown that it neutralizes SARS-CoV-2 and cross-reacts with SARS-CoV-1. EY6A Fab binds th...
Main Authors: | Zhou, D, Duyvesteyn, HME, Chen, C-P, Huang, C-G, Chen, T-H, Shih, S-R, Lin, Y-C, Cheng, C-Y, Cheng, S-H, Huang, Y-C, Lin, T-Y, Ma, C, Huo, J, Carrique, L, Malinauskas, T, Ruza, RR, Shah, PNM, Tan, TK, Rijal, P, Donat, RF, Godwin, K, Buttigieg, KR, Tree, JA, Radecke, J, Paterson, NG, Supasa, P, Mongkolsapaya, J, Screaton, GR, Carroll, MW, Gilbert-Jaramillo, J, Knight, ML, James, W, Owens, RJ, Naismith, JH, Townsend, AR, Fry, EE, Zhao, Y, Ren, J, Stuart, DI, Huang, K-YA |
---|---|
Format: | Journal article |
Language: | English |
Published: |
Springer Nature
2020
|
Similar Items
-
Structural insights into Frizzled3 through nanobody modulators
by: Hillier, J, et al.
Published: (2024) -
Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2
by: Huo, J, et al.
Published: (2020) -
Integrative structural biology of viruses
by: Duyvesteyn, HME
Published: (2019) -
Use of convalescent plasma therapy in eight individuals with mild COVID-19
by: F. Ji, et al.
Published: (2021-01-01) -
Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera
by: Supasa, P, et al.
Published: (2021)